The United Kingdom and the United States have hammered out a major trade agreement that will guarantee no import taxes on British medicine shipments going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these key goods will be held at zero for a timeframe of 36 months.
This development comes after earlier statements to significantly raise duties on patented drug products, with increases floated up to double the cost.
"This arrangement between the Britain reinforces the international landscape for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. medicine commerce," a statement noted.
Commercial Significance
Medicines constitute one of the the United Kingdom's biggest export categories to the US, which is by far the largest destination for leading British pharmaceutical firms.
Export figures show that in the 12 months prior to September, the UK exported pharmaceutical products valued at billions to the US. This figure represented a significant portion of British export trade in that timeframe.
"This guarantee safeguards work, stimulates investment and sets the stage for the UK to emerge as a international leader for medical research," a government official commented.
Specific British Pledges
The deal involves several specific pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise overall public funding on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Last year, refunds were more than 20%.
Recent Tensions
The deal takes place against a long-running row between the sector and the UK government over spending levels and regulatory access.
This friction were intensified by claims that American customers were charged significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its resources over the previous ten-year period.
